Literature DB >> 2073118

In vitro activities of cefoperazone and sulbactam singly and in combination against cefoperazone-resistant members of the family Enterobacteriaceae and nonfermenters.

R J Fass1, W W Gregory, R F D'Amato, J M Matsen, D N Wright, L S Young.   

Abstract

Among 28,000 isolates of the family Enterobacteriaceae and nonfermenters isolated at multiple medical centers, 1,084 (4%) were resistant to cefoperazone (MIC, greater than or equal to 64 micrograms/ml) and 1,711 (6%) exhibited cefoperazone MICs of 2 to 32 micrograms/ml. Ninety-six percent of these 2,795 isolates produced beta-lactamase, as determined by the nitrocefin test. Sulbactam alone (8 micrograms/ml) was inactive against 99.6% of the isolates other than Acinetobacter calcoaceticus and Pseudomonas cepacia. Sulbactam enhanced the activity of cefoperazone against 56% of the isolates of the family Enterobacteriaceae and 44% of the nonfermenters. In the presence of sulbactam concentrations of less than or equal to 8 micrograms/ml, 65% of the cefoperazone-resistant isolates had reductions in cefoperazone MICs of greater than or equal to 2 log2 dilution steps and were susceptible to less than or equal to 32 micrograms/ml. Antagonism was not observed.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2073118      PMCID: PMC172033          DOI: 10.1128/AAC.34.11.2256

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

Review 1.  The role of beta-lactamase inhibitors in chemotherapy.

Authors:  H C Neu
Journal:  Pharmacol Ther       Date:  1985       Impact factor: 12.310

2.  CP-45,899, a beta-lactamase inhibitor that extends the antibacterial spectrum of beta-lactams: initial bacteriological characterization.

Authors:  A R English; J A Retsema; A E Girard; J E Lynch; W E Barth
Journal:  Antimicrob Agents Chemother       Date:  1978-09       Impact factor: 5.191

3.  Synergistic activity of cefoperazone in combination with beta-lactamase inhibitors.

Authors:  K P Fu; H C Neu
Journal:  J Antimicrob Chemother       Date:  1981-03       Impact factor: 5.790

4.  Inconsistency of synergy between the beta-lactamase inhibitor CP-45,899 and beta-lactam antibiotics against multiply drug-resistant Enterobacteriaceae and pseudomonas species.

Authors:  R J Fass
Journal:  Antimicrob Agents Chemother       Date:  1981-02       Impact factor: 5.191

5.  Clavulanic acid and CP-45,899: a comparison of their in vitro activity in combination with penicillins.

Authors:  R Wise; J M Andrews; K A Bedford
Journal:  J Antimicrob Chemother       Date:  1980-03       Impact factor: 5.790

Review 6.  Contribution of beta-lactamases to bacterial resistance and mechanisms to inhibit beta-lactamases.

Authors:  H C Neu
Journal:  Am J Med       Date:  1985-11-29       Impact factor: 4.965

7.  CP-45,899 in combination with penicillin or ampicillin against penicillin-resistant Staphylococcus, Haemophilus influenzae, and Bacteroides.

Authors:  J A Retsema; A R English; A E Girard
Journal:  Antimicrob Agents Chemother       Date:  1980-04       Impact factor: 5.191

8.  Kinetic properties of two plasmid-mediated beta-lactamases from Klebsiella pneumoniae with strong activity against third-generation cephalosporins.

Authors:  R Labia; A Morand; K Tiwari; J S Pitton; D Sirot; J Sirot
Journal:  J Antimicrob Chemother       Date:  1988-03       Impact factor: 5.790

Review 9.  Cefoperazone: a review of its antimicrobial spectrum, beta-lactamase stability, enzyme inhibition, and other in vitro characteristics.

Authors:  R N Jones; A L Barry
Journal:  Rev Infect Dis       Date:  1983 Mar-Apr

10.  Changing patterns of resistance to new beta-lactam antibiotics. In vitro efficacy of cefoperazone against bacterial pathogens.

Authors:  R N Jones
Journal:  Am J Med       Date:  1984-07-31       Impact factor: 4.965

View more
  5 in total

1.  In vitro activities of quinolones, beta-lactams, tobramycin, and trimethoprim-sulfamethoxazole against nonfermentative gram-negative bacilli.

Authors:  R J Fass; J Barnishan; M C Solomon; L W Ayers
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

Review 2.  β-Lactams and β-Lactamase Inhibitors: An Overview.

Authors:  Karen Bush; Patricia A Bradford
Journal:  Cold Spring Harb Perspect Med       Date:  2016-08-01       Impact factor: 6.915

3.  Occurrence of variants with temperature-dependent susceptibility (TDS) to antibiotics among Stenotrophomonas maltophilia clinical strains.

Authors:  P Hejnar; M Kolár; V Hájek; D Koukalová; P Hamal
Journal:  Folia Microbiol (Praha)       Date:  2001       Impact factor: 2.099

4.  Synergistic effects of sulbactam in multi-drug-resistant Acinetobacter baumannii.

Authors:  Fatih Temocin; Fatma Sebnem Erdinc; Necla Tulek; Meryem Demirelli; Gunay Ertem; Sami Kinikli; Eda Koksal
Journal:  Braz J Microbiol       Date:  2015 Oct-Dec       Impact factor: 2.476

5.  Appropriate composites of cefoperazone-sulbactam against multidrug-resistant organisms.

Authors:  Chih-Cheng Lai; Chi-Chung Chen; Ying-Chen Lu; Tsuey-Pin Lin; Yin-Ching Chuang; Hung-Jen Tang
Journal:  Infect Drug Resist       Date:  2018-09-11       Impact factor: 4.003

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.